Svenska
Glossary
Search
Media Releases 2010
Media Archive
Presentations
Image Bank
Calendar
Media Contact
Media Releases 2010
Juni 22, 2010
NeuroNovas läkemedelskandidat sNN0029 för ALS får särläkemedelsstatus av amerikanska läkemedelsmyndigheten FDA
June 22, 2010
NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan drug designation by the FDA
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Sitemap
Site policy
Project Pipeline
Project
Indication
Pre-clin.
IND
Phase I/II
Phase II
Phase III
sNN0029
ALS
sNN0031
Parkinson's disease
More about our Projects
Business Development
NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.
